Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 31 for:    "Transitional Cell Carcinoma" | "Atezolizumab"

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03029832
Recruitment Status : Terminated (The study was prematurely terminated due to slow patient accrual and discontinuation of clinical development of MOXR0916 due to Sponsor's strategic priorities.)
First Posted : January 24, 2017
Results First Posted : May 31, 2019
Last Update Posted : May 31, 2019
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is a Phase II, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of MOXR0916 in combination with atezolizumab versus placebo and atezolizumab in participants with locally advanced or metastatic urothelial carcinoma (UC) who have not received prior systemic therapy in the locally advanced/metastatic setting and who are ineligible to receive cisplatin-based therapy.

Condition or disease Intervention/treatment Phase
Urothelial Carcinoma Drug: MOXR0916 Drug: Atezolizumab Phase 2

Detailed Description:
The study design has been amended after the decision to prematurely stop patient accrual due to enrollment challenges. As only 5 participants were enrolled, the study blinding will not be maintained, and placebo infusions will not be administered. Patients assigned to the MOXR0916 arm may continue study treatment with the combination of atezolizumab and MOXR0916 or with atezolizumab alone based on a discussion of benefit and risk with the treating investigator.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: The study design has been amended in that the study blinding will not be maintained.
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Actual Study Start Date : April 27, 2017
Actual Primary Completion Date : April 25, 2018
Actual Study Completion Date : April 25, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MOXR0916 plus Atezolizumab Drug: MOXR0916
MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Drug: Atezolizumab
Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Active Comparator: Atezolizumab Drug: Atezolizumab
Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.




Primary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Up to approximately 45 months ]
    PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first. Per RECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline); and an absolute increase of >= 5 millimeter (mm) in the sum of diameters.

  2. Overall Survival (OS) [ Time Frame: Up to approximately 45 months ]
    Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.


Secondary Outcome Measures :
  1. Objective Response (OR) According to RECIST v1.1 [ Time Frame: Up to approximately 45 months ]
    OR is defined as a complete response (CR) or partial response (PR) on two consecutive occasions >= 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

  2. Duration of Objective Response (DOR) According to RECIST v1.1 [ Time Frame: Up to approximately 45 months ]
    DOR is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1. Objective response is defined as a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

  3. Time to Pain Progression, Pain Palliation, and Fatigue Progression as Measured by Participant-Reported Severity According to the M. D. Anderson Symptom Inventory (MDASI) [ Time Frame: Up to approximately 45 months ]
    The MDASI is a cancer-related, self-reported questionnaire consisting of 19 items assessing symptom severity and interference with different aspects of a participant's life. The MDASI items are rated from 0 to 10, with 0 indicating that the symptom is either not present or does not interfere with the participant's activities and 10 indicating that the symptom is "as bad as you can imagine" or "interfered completely" with the participant's life.

  4. Percentage of Participants Reporting Symptom Interference With Daily Living at the Time of Progression According to the MDASI [ Time Frame: Up to approximately 45 months ]
    The MDASI is a cancer-related, self-reported questionnaire consisting of 19 items assessing symptom severity and interference with different aspects of a participant's life. The MDASI items are rated from 0 to 10, with 0 indicating that the symptom is either not present or does not interfere with the participant's activities and 10 indicating that the symptom is "as bad as you can imagine" or "interfered completely" with the participant's life.

  5. Percentage of Participants With Adverse Event (AEs) [ Time Frame: Up to approximately 45 months ]
    An adverse event is any untoward medical occurrence, regardless of causal attribution.

  6. Area Under the Plasma Drug Concentration-time Curve (AUC) of MOXR0916 and Atezolizumab [ Time Frame: Cycle 1 (each cycle is 21 days), Day 1: predose and 30 min. after atezolizumab infusion; Cycle 1, on Days 8 and 15. Cycles 2 4, Day 1: predose and 30 min. after atezolizumab infusion. Cycles 8, 12, and 16: predose ]
    AUC represents the body's exposure to an administered drug.

  7. Maximum Plasma Concentration (Cmax) of MOXR0916 and Atezolizumab [ Time Frame: Cycle 1 (each cycle is 21 days), Day 1: predose and 30 min. after atezolizumab infusion; Cycle 1, on Days 8 and 15. Cycles 2 4, Day 1: predose and 30 min. after atezolizumab infusion. Cycles 8, 12, and 16: predose ]
    Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose.

  8. Minimum Plasma Concentration (Cmin) of MOXR0916 and Atezolizumab [ Time Frame: Cycle 1 (each cycle is 21 days), Day 1: predose and 30 min. after atezolizumab infusion; Cycle 1, on Days 8 and 15. Cycles 2 4, Day 1: predose and 30 min. after atezolizumab infusion. Cycles 8, 12, and 16: predose ]
    Cmin refers to the minimum (trough) serum concentration of a drug in a specified compartment or test area of the body.

  9. Clearance of MOXR0916 and Atezolizumab [ Time Frame: Cycle 1 (each cycle is 21 days), Day 1: predose and 30 min. after atezolizumab infusion; Cycle 1, on Days 8 and 15. Cycles 2 4, Day 1: predose and 30 min. after atezolizumab infusion. Cycles 8, 12, and 16: predose ]
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

  10. Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to MOXR0916 and Atezolizumab [ Time Frame: Cycles 1 - 4 and 8, 12, and 16 (each cycle is 21 days), Day 1: predose ]
    ATAs may be produced by the body in response to an administered drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >= 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of <= 2
  • Life expectancy >= 12 weeks
  • Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma (UC)
  • Availability of a representative formalin-fixed paraffin-embedded tumor specimen
  • No prior systemic therapy for inoperable locally advanced or metastatic UC
  • Ineligible for cisplatin-based chemotherapy as defined by any one of the following criteria: Impaired renal function (glomerular filtration rate [GFR] > 30 but < 60 milliliter/minute [mL/min]); National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0 Grade >= 2 audiometric hearing loss (of 25 Decibel at two contiguous frequencies or more severe); NCI CTCAE v 4.0 Grade >= 2 peripheral neuropathy; ECOG Performance Status of 2
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1
  • Adequate hematologic and end-organ function

Exclusion Criteria:

  • Significant cardiovascular disease
  • Known clinically significant liver disease
  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
  • Prior treatment with CD137 or OX40 agonists, anti−cytotoxic T-lymphocyte-associated protein (CTLA4), anti−programmed death-1 (PD-1), anti- programmed death-ligand 1 (PD-L1), anti-CD-27, anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) therapeutic antibody or pathway-targeting agents
  • Untreated central nervous system (CNS) metastases or active (progressing or requiring corticosteroids for symptomatic control) CNS metastases
  • Any history of leptomeningeal disease
  • Malignancies other than UC within 5 years prior to Cycle 1, Day 1
  • History of autoimmune disease
  • History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography scan
  • Active hepatitis B and C virus infection
  • Positive HIV test at screening
  • Active tuberculosis
  • Prior allogeneic stem cell or solid organ transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03029832


  Show 22 Study Locations
Sponsors and Collaborators
Genentech, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
  Study Documents (Full-Text)

Documents provided by Genentech, Inc.:

Layout table for additonal information
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT03029832     History of Changes
Other Study ID Numbers: GO39590
2016-004165-58 ( EudraCT Number )
First Posted: January 24, 2017    Key Record Dates
Results First Posted: May 31, 2019
Last Update Posted: May 31, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atezolizumab
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Cisplatin
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs